Last reviewed · How we verify
CM082 plus JS001
At a glance
| Generic name | CM082 plus JS001 |
|---|---|
| Also known as | Vorolanib, Toripalimab, Vorolanib plus Toripalimab Injection |
| Sponsor | AnewPharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma (PHASE2)
- CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). (PHASE2)
- CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) (PHASE2)
- Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |